MedTrace Logo

Cannabis Effects on Opioid Self-Administration

NCT07668635 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-08-20

No results posted yet for this study

Summary

The study will enroll participants with opioid use disorder and participants will reside at the University of Kentucky Hospital for this 6-week inpatient trial. During this time, double-blind doses of cannabis and opioids will be administered. The goal of the project is to determine if cannabis can alter the drive/desire to take opioids.

Conditions

Interventions

DRUG

Cannabis

Cannabis is administered three times daily during the active cannabis treatment period.

DRUG

Placebo Cannabis

Matched placebo cannabis is administered three times daily during the placebo treatment period.

DRUG

Intranasal Opioid Agonist

Intranasal opioid agonists are administered during sample and self-administration sessions

DRUG

Oral Opioid Agonist

Oral opioid agonist maintenance doses are administered four times daily throughout study participation.

Sponsors & Collaborators

  • Shanna Babalonis, PhD

    lead OTHER

Principal Investigators

  • Shanna Babalonis, PhD · University of Kentucky, College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2030-07-30
Completion
2031-07-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07668635 on ClinicalTrials.gov